Gilead Sciences Valuation

Gilead Sciences retains regular Real Value of USD88.67 per share. The prevalent price of the corporation is USD71.01. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences from evaluating the corporation fundamentals such as Current Valuation of 111.07B, Return On Asset of 22.43% and Return On Equity of 85.39% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

Valuation Drivers Correlation

Selected Gilead Sciences Inc Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
Investment Horizon     30 Days    Login   to change

Gilead Sciences Total Value Analsys

Gilead Sciences Inc is currently projected to have valuation of 111.07 B with market capitalization of 96.27 B, debt of 27.07 B, and cash on hands of 12.27 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gilead Sciences fundamentals before making equity appraisal based on the enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
111.07 B96.27 B27.07 B12.27 B

Gilead Sciences Investor Information

About 83.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 10.82. Gilead Sciences Inc last dividend was issued on December 13, 2016. This company had 2:1 split on January 28, 2013. Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. To learn more about GILEAD SCIENCES call John Martin at 650-574-3000 or check out http://www.gilead.com.

Gilead Sciences Asset Utilization

Gilead Sciences harnesses its working resources almost 22.43 (percent), generating USD0.2243 for each dollar of working resources held by the corporation. An expanding assets utilization attests that the company is being more effective with each dollar of working resources it retains. In other words assets utilization of Gilead Sciences shows how effective it operates for each dollar spent on its working resources

Gilead Sciences Ownership Allocation (%)

Gilead Sciences secures a total of 1.32 Billion outstanding shares. Majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investers are referred to non-private investors that are looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to different set of regulations than regular investors in Gilead Sciences Inc. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of how profitable the company is, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns from it at some point.
 Ownership % 
Benchmark  Embed   Values 

Gilead Sciences Profitability Analysis

The company reported previous year revenue of 31.58 B. Net Income was 15.08 B with profit before overhead, payroll, taxes, and interest of 28.63 B.
 Profitability 
Benchmark  Embed   Values 
Under Valued
January 22, 2017
71.01
Market Value
Downside upside
88.67
Real Value
Target Price Odds
 Above  Below  
92.75
Upside
Upside upside
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences is based on 1 month time horizon. Increasing Gilead Sciences time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Recommendations
Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
105.0Buy13Odds
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  
Tax Efficiency
Gilead Sciences Tax Efficiency History
Revenue
Gilead Sciences Revenue
Based on latest financial disclosure Gilead Sciences Inc reported 31.58 B of revenue. This is much higher than that of the sector, and significantly higher than that of Revenue industry, The Revenue for all stocks is over 1000% lower than the firm.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.